30 October 2019 Press Conference 30 October 2019 Press Conference: Final results M72/AS01E candidate vaccine
The results from the M72/AS01E TB vaccine against tuberculosis (TB) was presented at the TBScience 2019 conference on Tuesday 29 October 2019.
The study demonstrated a sustained level of protection against active tuberculosis (TB). Watch the video online. Click here.
Professor Mark Hatherill, SATVI Director and Principal Investigator
The vaccine, known as M72/AS01E and developed by GlaxoSmithKline (GSK), contributed to preventing TB in 50 percent of people receiving it, representing a significant advancement towards ending the TB emergency. This would be the first new vaccine for preventing TB – the leading cause of death by infectious disease – in nearly a century. The only vaccine against TB currently available is BCG, which was developed in 1921 and does not provide proven and consistent protection in adults in TB-endemic countries.